Skip Navigation


Annals of Oncology Advance Access originally published online on January 17, 2007
Annals of Oncology 2007 18(6):977-984; doi:10.1093/annonc/mdl475
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/6/977    most recent
mdl475v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Valabrega, G
Right arrow Articles by Aglietta, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valabrega, G
Right arrow Articles by Aglietta, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

reviews

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer

G Valabrega*,{dagger}, F Montemurro{dagger} and M Aglietta

University Division of Medical Oncology and Haematology, Institute for Cancer Research and Treatment, Strada Provinciale 142, 10060 Candiolo, Torino, Italy

* Correspondence to: Dr G. Valabrega, University Division of Medical Oncology and Haematology, Institute for Cancer Research and Treatment (IRCC). Tel: +39-119933253; Fax: +39-0119933299; E-mail: giorgio.valabrega{at}ircc.it

Trastuzumab is a humanized mAb directed against the extracellular domain of the tyrosine kinase receptor HER2. Trastuzumab has shown clinical activity in HER2-overexpressing breast cancers and, at present, is currently approved for patients whose tumours have this abnormality, in both the metastatic and the adjuvant setting. Several issues about its optimal use, however, are still unresolved. One of the reasons for these uncertainties lies in the absence of conclusive data about its mechanism of action and possible primary or acquired resistance mechanisms. Therefore, clinical questions such as how to optimize patient selection, how to prevent resistance to trastuzumab, or what is the optimal management of those patients whose tumours progress during treatment still await convincing answers. This review summarises the current knowledge on the preclinical and clinical evidence about the mechanism of action of trastuzumab and on the mechanisms underlying the development of resistance and also briefly discusses their possible clinical implications.

Key words: breast neoplasms, HER2, mechanism of action, resistance, trastuzumab

Received for publication May 25, 2006. Revision received September 11, 2006. Accepted for publication November 30, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
A. J. Najy, K. C. Day, and M. L. Day
The Ectodomain Shedding of E-cadherin by ADAM15 Supports ErbB Receptor Activation
J. Biol. Chem., June 27, 2008; 283(26): 18393 - 18401.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. J. Dahabreh, H. Linardou, F. Siannis, G. Fountzilas, and S. Murray
Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Oncologist, June 1, 2008; 13(6): 620 - 630.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
J. King, J. Waxman, and H. Stauss
Advances in tumour immunotherapy
QJM, May 13, 2008; (2008) hcn050v1.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney
Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
Cancer Res., March 1, 2008; 68(5): 1471 - 1477.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Varchetta, N. Gibelli, B. Oliviero, E. Nardini, R. Gennari, G. Gatti, L. S. Silva, L. Villani, E. Tagliabue, S. Menard, et al.
Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2
Cancer Res., December 15, 2007; 67(24): 11991 - 11999.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. C. Liu, T. Deng, R. S. Lehal, J. Kim, and E. Zacksenhaus
Identification of Tumorsphere- and Tumor-Initiating Cells in HER2/Neu-Induced Mammary Tumors
Cancer Res., September 15, 2007; 67(18): 8671 - 8681.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.